An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.

[1]  P. Poole,et al.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[2]  Y. Nakanishi,et al.  Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways. , 2013, International immunology.

[3]  T. Yokomizo,et al.  Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand[S] , 2013, Journal of Lipid Research.

[4]  M. Cazzola,et al.  Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. , 2013, The Lancet. Respiratory medicine.

[5]  H. Watz,et al.  Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. , 2013, Pulmonary pharmacology & therapeutics.

[6]  K. Rabe,et al.  Phosphodiesterase-4 inhibitor therapy for lung diseases. , 2013, American journal of respiratory and critical care medicine.

[7]  M. Kubo,et al.  Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  I. Hishinuma,et al.  Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[9]  A. Condliffe,et al.  The neutrophil in chronic obstructive pulmonary disease. , 2013, American journal of respiratory cell and molecular biology.

[10]  P. Davis,et al.  Higher versus lower oxygen concentrations titrated to target oxygen saturations during resuscitation of preterm infants at birth , 2012 .

[11]  Domenico Spina,et al.  Selective PDE inhibitors as novel treatments for respiratory diseases. , 2012, Current opinion in pharmacology.

[12]  S. Rennard,et al.  PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease , 2012, Clinical pharmacology and therapeutics.

[13]  K. Austen,et al.  Cysteinyl Leukotrienes Impair Hypoxic Pulmonary Vasoconstriction in Endotoxemic Mice , 2011, Anesthesiology.

[14]  Richard Graham Knowles,et al.  GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization , 2011, Journal of Pharmacology and Experimental Therapeutics.

[15]  Richard Graham Knowles,et al.  In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[16]  N. Suttorp,et al.  Innate immune recognition in infectious and noninfectious diseases of the lung. , 2010, American journal of respiratory and critical care medicine.

[17]  J. Vestbo,et al.  A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD , 2009, European Respiratory Journal.

[18]  D. Aronoff,et al.  Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.

[19]  N. Hoefgen,et al.  In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[21]  C. Chan,et al.  PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway , 2001, Neuropharmacology.

[22]  A. Sapirstein,et al.  Attenuation of Hypoxic Pulmonary Vasoconstriction by Endotoxemia Requires 5-Lipoxygenase in Mice , 2001, Circulation research.

[23]  P. Ward,et al.  Expression of lung vascular and airway ICAM-1 after exposure to bacterial lipopolysaccharide. , 1997, American journal of respiratory cell and molecular biology.

[24]  T. Standiford,et al.  Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. , 1995, Journal of immunology.

[25]  P. Ward,et al.  Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. , 1995, Journal of immunology.

[26]  J. Paulauskis,et al.  Functional characterization of rat chemokine macrophage inflammatory protein-2 , 1995, Inflammation.

[27]  J. Paulauskis,et al.  Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation. , 1992, The American journal of pathology.

[28]  N. Voelkel,et al.  Endotoxin-induced lung injury in rats: role of eicosanoids. , 1989, Journal of applied physiology.

[29]  H. Inoue,et al.  Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. , 2003, American journal of respiratory and critical care medicine.

[30]  A. Ishizaka,et al.  Effects of ONO-1078, a peptide leukotriene antagonist, on endotoxin-induced acute lung injury. , 1994, American journal of respiratory and critical care medicine.